74.95USD-0.78%Mkt Cap: 10.56B USDP/E: —Last update: 2026-05-22
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasir…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap10.56B USD
Enterprise Value10.23B USD
Revenue (TTM)622.01M USD
Gross Profit622.01M USD
Net Income (TTM)-1.63M USD
Revenue/Share4.471 USD
Last Price74.95 USD
Fiscal Year EndSep 2025
MR QuarterMar 2026
Employees711
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS04280A1007
Valuation
P/E (Trailing)—
P/E (Forward)-17.40
PEG—
EV/EBITDA-52.04
EV/Revenue16.44
P/S17.11
P/B17.29
EPS (TTM)-2.27
EPS (Forward)-4.34
52W Range
14.3089% of range82.26
52W High82.26 USD
52W Low14.30 USD
Profitability
Gross Margin100.00%
Oper. Margin-191.57%
EBITDA Margin-31.60%
Profit Margin-0.20%
ROE-0.35%
ROA-0.12%
Growth
Revenue Growth-86.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF179.55M USD
CapEx (TTM)22.67M USD
FCF Margin-7.41%
FCF Yield-0.44%
Net Debt-398.40M USD
Net Debt/EBITDA2.03
Balance Sheet
Debt/Equity0.79
Current Ratio6.23
Quick Ratio6.09
Book Value/Sh4.368 USD
Cash/Share12.65 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateNov 17, 2011
Analyst Consensus
Rating1.6 (Buy)
Target (Mean)88.17 USD
Target Range46.00 USD – 110.00 USD
# Analysts12
Ownership
Shares Out.140.86M
Float122.81M
Insiders3.76%
Institutions88.72%
Short Interest
Short Ratio7.3d
Short % Float12.83%
Short % Out.9.20%
Shares Short12.94M
Short (prev mo.)13.00M
Technical
SMA 5067.71 (+10.7%)
SMA 20052.81 (+41.9%)
Beta1.29
S&P 52W Chg28.31%
Avg Vol (30d)1.84M
Avg Vol (10d)1.90M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—